Liverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service at More Than 100 Community Pharmacies
Today, Liverpool Clinical Commissioning Group (CCG) and Community Pharmacy Liverpool kicked off a new clinical service that will allow more than 100 pharmacies to offer a 10-minute, point-of-care test to differentiate bacterial from viral respiratory infection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006163/en/
Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infections in 10 minutes. The FebriDx test will be used for patients with an acute cough at pharmacies under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first. (Photo: Business Wire)
The test, named FebriDx®, will be used for patients with an acute cough at pharmacies across Liverpool under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first.
“It is often difficult for healthcare providers to determine if a respiratory infection is bacterial or viral without this type of rapid testing because the symptoms are nearly identical,” said Peter Johnstone, Head of Medicines Optimisation for Liverpool CCG.
“FebriDx lends itself to the Pharmacy First initiative really well – the test uses a small finger stick blood sample to differentiate a bacterial from viral acute respiratory infection in just 10 minutes, and we’re starting to offer this in local pharmacies to help ensure people get the right treatment.”
The FebriDx test has already been in use in some hospitals and GP Surgeries across the UK for three years, but this is the first time it has been used in the Merseyside region.
“Our goal is to provide patients with more convenient access to testing and treatment for acute cough under a new Patient Group Direction (PGD),” explains Matt Harvey, Chief Officer of Community Pharmacy Liverpool. “With the high volumes of patients with coughs and respiratory problems during the winter season, we see a real opportunity to bring this test into local pharmacies to help us provide treatment for patients more quickly – without the need for a GP appointment or prescription first.”
In addition to the convenience, clinical studies show that this test allows healthcare providers to rule out bacterial infections for their patients with 99% confidence, which can help reduce the unnecessary use of antibiotics and reduce antimicrobial resistance.
To learn more about this service, please visit: www.liverpoolccg.nhs.uk
About NHS Liverpool CCG
NHS Liverpool Clinical Commissioning Group (CCG) is responsible for commissioning (planning and buying) hospital and community health services for the people of Liverpool. It has a budget of around £840m a year. The CCG is made up of representatives from each of the city’s 85 GP practices, and is led by a Governing Body consisting of GPs from across the city. Visit the website at: www.liverpoolccg.nhs.uk
About Community Pharmacy Liverpool
Community Pharmacy Liverpool is Liverpool’s local pharmaceutical committee (LPC), an organisation which represents community pharmacies across the city. Visit the website at: www.liverpool-lpc.org.uk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111006163/en/
Contact information
NHS Liverpool CCG Media Contact
Anna Kettle, Senior Communications Manager, NHS Liverpool CCG
tel: 0151 295 3540, email: anna.kettle@liverpoolccg.nhs.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 21:30:00 EET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 19:30:00 EET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 17:00:00 EET | Press release
The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data center expansion (~4%). Crucially, the report finds that this additional demand does not have to result in competition between industry and communities. Today, global water systems proces
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 17:00:00 EET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 17:00:00 EET | Press release
Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluated vendors in the Current Offering category. Analysts praised the platform’s "impressive vision and innovation," specificall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom